BAUSCH PLUS LOMB CORPBB

BAUSCH PLUS LOMB CORP

15.55CADD
−0.63−3.89%
At close at May 30, 20:00 GMT
CAD
No trades
See on Supercharts

BLCO fundamentals

Key facts

Market capitalization‪5.60 B‬CAD
Basic EPS (TTM)−1.48CAD
Founded1853
Employees (FY)‪13.5 K‬
CEOBrenton L. Saunders
Websitebausch.com
About

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Ownership
‪‪353.40 M‬‬
Closely held shares
‪‪316.73 M‬‬ (89.63%)
Free Float shares
‪‪36.66 M‬‬ (10.37%)
Closely held shares
‪‪316.73 M‬‬ (89.63%)
Free Float shares
‪‪36.66 M‬‬ (10.37%)
Capital structure
Market cap
‪‪5.60 B‬‬
Debt
‪‪6.95 B‬‬
Minority interest
‪‪103.62 M‬‬
Cash & equivalents
‪‪309.42 M‬‬
Enterprise value
‪‪12.35 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪5.60 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
0.86x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
0.86x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪0.40‬
‪0.80‬
‪1.20‬
‪1.60‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−21%‬
‪−14%‬
‪−7%‬
‪0%‬
‪7%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−700.00 M‬‬
‪0.00‬
‪‪700.00 M‬‬
‪‪1.40 B‬‬
‪‪2.10 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−600.00 M‬‬
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
‪‪1.80 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−600.00 M‬‬
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
‪‪1.80 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Vision Care
Pharmaceuticals
Surgical
By country
Period: 2024
United States and Puerto Rico
Other
China
France
Japan
Germany
United Kingdom
Canada
Russia
Spain

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬
Actual
Estimate
Earnings
Next:Jul 30, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪−0.12‬
‪0.00‬
‪0.12‬
‪0.24‬
‪0.36‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
BLCO has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−2.50 B‬‬
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬
Assets
Liabilities